PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Bar-Or, Amit
TI  - RPC1063 Safe and Effective in RRMS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 12--13
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/12.short
4100  - http://mdc.sagepub.com/content/14/29/12.full
AB  - Treatment with the sphingosine 1-phosphate (S1P) receptor modulator, RPC1063, resulted in a substantial decrease in gadolinium-enhancing (Gd+) lesions and the number of new or enlarging T2 lesions in patients with relapsing-remitting multiple sclerosis (RRMS). This article presents data from the Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients trial [Radiance Study; NCT01628393].